Poor
Not Aligned
Patient Risk:
Medium
Summary
Most statements assess general sourcing/quality of toremifene rather than FDA label content. The only label-relevant content (QT prolongation risk/contraindications/avoidance/monitoring) is not actually stated in the listed AI-generated sentences to be evaluated, so label alignment cannot be substantiated. Several items are generic and not supported or contradicted by the provided prescribing information excerpts.
Category Scores
Accurate Statements
Toremifene is commonly sold as toremifene citrate tablets for oral administration.
Not supported in the provided prescribing information excerpts (indications/dosage/warnings provided do not state market formulation or marketing wording).
Unsupported Statements
Toremifene citrate is a prescription medicine in many places.
Not addressed in the provided prescribing information excerpts.
Legitimate supply of toremifene citrate typically goes through licensed pharmacies or authorized distributors.
Not addressed in the provided prescribing information excerpts.
Toremifene is commonly sold as toremifene citrate tablets for oral administration.
Provided label excerpt confirms oral dosing for FARESTON (60 mg once daily orally) but does not support statements about how it is commonly sold in markets.
Available toremifene citrate tablet strengths vary by market.
Not addressed in the provided prescribing information excerpts.
The tablet strength should be matched to what the prescriber ordered.
Not addressed in the provided prescribing information excerpts.
Unlicensed/unauthorized online pharmacy vendors may sell toremifene citrate without a prescription.
Not addressed in the provided prescribing information excerpts.
Unofficial sources can sell incorrect ingredients.
Not addressed in the provided prescribing information excerpts.
Unofficial sources can sell incorrect strength.
Not addressed in the provided prescribing information excerpts.
Unofficial sources can sell counterfeit products.
Not addressed in the provided prescribing information excerpts.
Unofficial sources can sell products that were stored improperly.
Not addressed in the provided prescribing information excerpts.
Improper storage can affect the quality of toremifene citrate products.
Provided excerpts do not include storage/stability/handling statements.
Contradictions
Important Omissions
FDA label-aligned safety information regarding QT prolongation (boxed warning content; contraindications for congenital/acquired QT prolongation and uncorrected hypokalemia/hypomagnesemia; electrolyte correction and monitoring; avoidance of QT-prolonging drugs; avoidance of strong CYP3A4 inhibitors with QT risk; ECG guidance as clinically indicated).
Importance:
High
FDA label-aligned indication (metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors) and dosage/administration (FARESTON 60 mg once daily orally; generally continued until disease progression).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The evaluated statements primarily concern sourcing/quality of toremifene and do not include FDA label-based QT safety contraindications or interaction/monitoring warnings. Omission of these label-specific safety elements could lead to incomplete risk communication, though no direct contradiction of the label is present.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
The provided AI-generated statements do not substantiate FDA label claims and omit key label-specific QT prolongation contraindications and warnings relevant to the supplied prescribing information.
Suggested Improvement
Replace or supplement the sourcing/market-general statements with FDA label-supported content: indication, dosage (60 mg once daily orally), QT prolongation boxed warning and contraindications (congenital/acquired QT prolongation; uncorrected hypokalemia/hypomagnesemia), and warnings/precautions (correct electrolytes, monitor periodically and obtain ECGs as clinically indicated; avoid QT-prolonging drugs and strong CYP3A4 inhibitors/grapefruit juice; interruption/monitoring guidance if concomitant QT risk drugs are required).